Publicaciones (118) Publicaciones de LUIS BRIEVA RUIZ

2024

  1. Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?

    Pharmaceuticals, Vol. 17, Núm. 4

  2. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

    Neurologia, Vol. 39, Núm. 2, pp. 196-208

  3. Effects of Vortioxetine on Cognition and Fatigue in Patients with Multiple Sclerosis and Depression: A Case Series Study

    CNS & neurological disorders drug targets, Vol. 23, Núm. 3, pp. 395-401

2023

  1. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies

    Journal of Neurology, Vol. 270, Núm. 5, pp. 2380-2391

  2. Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis

    Brain Communications, Vol. 5, Núm. 2

  3. Association of Serum Neurofilament Light Chain Levels at Disease Onset with Disability Worsening in Patients with a First Demyelinating Multiple Sclerosis Event Not Treated with High-Efficacy Drugs

    JAMA Neurology, Vol. 80, Núm. 4, pp. 397-403

  4. Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 9, Núm. 2

  5. Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis

    Patient Preference and Adherence, Vol. 17, pp. 1431-1439

  6. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study

    Multiple Sclerosis Journal, Vol. 29, Núm. 14, pp. 1808-1818

  7. Mitochondrial Aconitase Enzymatic Activity: A Potential Long-Term Survival Biomarker in the Blood of ALS Patients

    Journal of Clinical Medicine, Vol. 12, Núm. 10

  8. Monitoring response to disease-modifying treatment in multiple sclerosis

    Neurology Perspectives, Vol. 3, Núm. 2

  9. Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot study

    Scientific Reports, Vol. 13, Núm. 1

  10. Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset

    Multiple Sclerosis Journal, Vol. 29, Núm. 14, pp. 1776-1785

  11. Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

    Journal of Clinical Medicine, Vol. 12, Núm. 23

  12. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  13. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

    Frontiers in immunology, Vol. 13, pp. 842354

  2. Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders

    The Lancet Neurology, Vol. 21, Núm. 10, pp. 899-910

  3. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  4. Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 68